Blood-Brain Barrier Permeability in Patients With Reversible Cerebral Vasoconstriction Syndrome Assessed With Dynamic Contrast-Enhanced MRI
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received April 14, 2021
- Accepted in final form August 23, 2021
- First Published September 9, 2021.
Article Versions
- Previous version (September 9, 2021 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- Chia-Hung Wu, MD,
- Jiing-Feng Lirng, MD,
- Hsiu-Mei Wu, MD,
- Yu-Hsiang Ling, MD,
- Yen-Feng Wang, MD, PhD,
- Jong-Ling Fuh, MD,
- Chung-Jung Lin, MD,
- Kan Ling, MD,
- Shuu-Jiun Wang, MD* and
- Shih-Pin Chen, MD, PhD*
- Chia-Hung Wu, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Ministry of Science and Technology of Taiwan, MOST 110- 2314-B-075-005-, Principal Investigator, 2021 (2) Taipei Veterans General Hospital, Taiwan, V109B-009, Principal Investigator, 2020
NONE
(1)Yen Tjing Ling Medical Foundation, CI-109-3 (2) Vivian W. Yen Neurological Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Jiing-Feng Lirng, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hsiu-Mei Wu, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yu-Hsiang Ling, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yen-Feng Wang, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Taiwan Ministry of Science and Technology, NSC 102-2314-B-075-054 (principal investigator, 1 year), NSC-103-2314-B-075-056 (principal investigator, 1 year), NSC 100-2314-B-010-018-MY3 (co-investigator, 3 years) (2) Taipei Veterans General Hospital, V102B-039 (principal investigator, 1 year), V103B-010 (principal investigator, 1 year), V104B-007 (principal investigator, 1 year)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jong-Ling Fuh, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Taiwan National Science Council and Taipei-Veterans General Hospital.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chung-Jung Lin, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kan Ling, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Shuu-Jiun Wang, MD* and
(1) Eli Lilly (Commercial) (2) Norvatis (Commercial)
NONE
(1) Pfizer Taiwan (Speaking honoraria, commercial) (2) Eli Lilly Taiwan (Speaking honoraria, commercial) (3) Daiichi-Sankyo (Moderator honoraria, commerical) (4) AbbVie (Speaking honoraria, commercial)
Editor, Journal of the Chinese Medical Association, 2005- Associate editor, Cephalalgia, 2009- Associate editor for headache section, MedLink Neurology, 2009- Associate editor, Headache, 2013-2020 Associate editor, Journal of Headache and Pain, 2012-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Ministry of Science and Technology of Taiwan [MOST 108-2314-B-010-023-MY3 and MOST 110-2321-B-010-005-] (2) Taipei-Veterans General Hospital [VGH-110C-166, VGH- 110E-005-1 ] (3) Brain Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan
NONE
(1) Taiwan Headache Society
NONE
NONE
NONE
NONE
NONE
NONE
- Shih-Pin Chen, MD, PhD*
NONE
NONE
NONE
I have served as Associate Editor of Cephalalgia and Cephalalgia Reports since 2020.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Brain Research Center, National Yang Ming Chiao Tung University, from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (2) Ministry of Science and Technology, Taiwan, MOST-107-2314-B-010-021, 108-2314-B-010-022-MY3, 110-2326-B- A49A-501-MY3 & 110-2321-B-010-005- (3)Taipei Veterans General Hospital, Taiwan, V108C-066, V109C-139 & V109D52- 001-MY3-1
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Radiology (C.-H.W., J.-F.L., H.-M.W., C.-J.L., K.L.), Department of Neurology, Neurological Institute (Y.-H.L., Y.-F.W., J.-L.F., S.-J.W., S.-P.C.), and Division of Translational Research, Department of Medical Research (S.-P.C.), Taipei Veterans General Hospital; and Institute of Clinical Medicine (C.-H.W., S.-P.C.), School of Medicine (C.-H.W., J.-F.L., H.-M.W., Y.-H.L., Y.-F.W., J.-L.F., C.-J.L., K.L., S.-J.W., S.-P.C.), and Brain Research Center (Y.-F.W., J.-L.F., S.-J.W., S.-P.C.), National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Correspondence
Dr. Chen chensp1977{at}gmail.com
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Author Response: Blood Brain Barrier Permeability in Patients With Reversible Cerebral Vasoconstriction Syndrome Assessed With Dynamic Contrast-Enhanced MRI
- Shih-Pin Chen, Neurologist, Professor, Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
- Shuu-Jiun Wang, Neurologist, Professor, Director, Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
- Chia-Hung Wu, Neuroradiologist, Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan
Submitted November 26, 2021 - Reader Response: Blood Brain Barrier Permeability in Patients With Reversible Cerebral Vasoconstriction Syndrome Assessed With Dynamic Contrast-Enhanced MRI
- Vinod K Gupta, Physician-Medical Director, GUPTA MEDICAL CENTRE, MIGRAINE-HEADACHE INSTITUTE, S-407, Greater Kailash-Part Two, New Delhi, INDIA-110048
Submitted October 30, 2021
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.